Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-specific immunoglobulin idiotype on malignant B cells (Idiotype (Id))
- Target
- Idiotype (Id)
- Molecular classification
- Other (clonotypic immunoglobulin variable-region epitope on B-cell receptor)
01
Overview
The tumor-specific immunoglobulin idiotype is the unique set of antigenic determinants (idiotopes) located mainly within the complementarity-determining regions of the immunoglobulin variable domains on malignant B cells; because B-cell malignancies are monoclonal, all tumor cells share the same surface-immunoglobulin idiotype, making it a truly tumor-specific antigen that can be targeted by patient-specific anti-idiotype antibodies, protein/DNA vaccines, or dendritic cell–based vaccines, and monitored via serum idiotype levels for disease burden and response
- Other names
- immunoglobulin idiotypetumor-specific idiotypeclonotypic idiotypesurface-immunoglobulin idiotypeId
02
Mechanism of action
Antibody binding to clonotypic idiotype on surface immunoglobulin leading to immune-mediated killing; Active vaccination inducing anti-idiotype antibodies and T-cell responses against idiotype-derived idiotopes; Dendritic cell presentation of idiotype to elicit tumor-specific T-cell immunity
03
Biological functions
Immune response (antigenic determinants/idiotopes on B-cell receptor variable regions)Tumor antigen/neoantigen surrogate for immunotherapy
04
Disease associations
Cancer (B-cell malignancies including B-cell lymphoma, chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia)
05
Safety considerations
Extreme tumor specificity leads to individualized manufacturing complexityPotential induction of regulatory T cells when targeting shared idiotopes (e.g., J-region peptides) that can dampen Id-specific responsesVariable immunogenicity and need for potent adjuvantsClinical logistics and time-to-produce for personalized vaccines
06
Interacting drugs
Patient-specific anti-idiotype monoclonal antibodies
3 more in the full profile.
07
Biomarkers
Serum idiotype (Id) levels as a tumor burden marker and minimal residual disease indicatorDetection of idiotype-specific immune responses post-vaccination
Beyond the preview
Go deeper on Tumor-specific immunoglobulin idiotype on malignant B cells (Idiotype (Id)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-specific immunoglobulin idiotype on malignant B cells (Idiotype (Id)).